From T cells to NK cells and macrophages: progress and challenges in CAR-based therapies and the involved gene delivery systems
New approaches to engineer immune cells beyond T cells could make cancer immunotherapy safer, more affordable, and effective against previously hard-to-treat tumors.
This review covers the expansion of CAR technology from T cells to NK cells and macrophages, addressing manufacturing and safety limitations of current CAR-T. It highlights non-viral gene delivery innovations that could make CAR-based immunotherapies more accessible and effective against solid tumors.
What the study was
- Study design
- Narrative review
- Population
- Cancer patients (hematologic and solid tumors)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- International Journal of Pharmaceutics
Why it surfaced
Useful overview of next-gen CAR therapies including CAR-NK and CAR-M. Review article without novel data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.